HRG-β1 inhibitors are a specialized class of compounds that act by modulating the activity of the HRG-β1 protein, which is involved in a variety of cellular signaling processes. These inhibitors typically function by binding to the HRG-β1 protein or its associated receptors, disrupting its interaction with other proteins or ligands necessary for its normal activity. Structurally, HRG-β1 inhibitors can range from small molecules to larger, more complex compounds such as peptides. The design of these inhibitors often incorporates key functional groups that enable strong binding interactions, such as hydrogen bonds, van der Waals forces, and electrostatic interactions with the target protein or receptor. This binding blocks HRG-β1's ability to engage in its usual role in signal transduction, thereby inhibiting downstream biological processes associated with its activity.
From a chemical perspective, HRG-β1 inhibitors are optimized for stability and selectivity. They are often engineered to resist degradation under various conditions, including enzymatic or oxidative breakdown, which ensures that they retain their inhibitory function in different environments. These compounds also exhibit diverse physical properties, such as solubility and permeability, which are important considerations for their effective interaction with the HRG-β1 target in biological systems. Additionally, the kinetics of HRG-β1 inhibitors can vary, with some showing rapid, reversible binding, while others form more prolonged, potentially irreversible interactions with their target. These characteristics are fine-tuned through careful chemical synthesis and structural modification to achieve the desired inhibitory effect, with the ultimate goal of efficiently disrupting HRG-β1 activity at a molecular level.
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $41.00 | 4 | |
Inibe as enzimas ciclo-oxigenase, afectando potencialmente a inflamação e as vias de coagulação. | ||||||
Warfarin | 81-81-2 | sc-205888 sc-205888A | 1 g 10 g | $72.00 $162.00 | 7 | |
Inibe os factores de coagulação dependentes da vitamina K, alterando potencialmente as vias de coagulação. | ||||||
Rivaroxaban | 366789-02-8 | sc-208311 | 2 mg | $155.00 | 18 | |
Inibe diretamente o Fator Xa, afectando possivelmente a cascata de coagulação relacionada com a função da HRG-β1. | ||||||
Apixaban | 503612-47-3 | sc-364406 sc-364406A | 10 mg 50 mg | $235.00 $622.00 | 2 | |
Inibidor do fator Xa, pode alterar a formação de trombina e afetar as vias de sinalização relacionadas. | ||||||
Clopidogrel | 113665-84-2 | sc-507403 | 1 g | $120.00 | 1 | |
Inibe o recetor P2Y12 ADP nas plaquetas, com potencial impacto na agregação plaquetária e vias relacionadas. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inibidor da tirosina quinase, pode afetar as vias de sinalização celular relacionadas com o crescimento e a adesão das células. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inibe múltiplos receptores tirosina-quinases, afectando potencialmente a angiogénese e a sinalização relacionada. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Glucocorticoide que modula a inflamação, influenciando potencialmente as vias de resposta imunitária. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Inibe a dihidrofolato redutase, afectando potencialmente a proliferação celular e as funções imunitárias. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Modula a atividade imunitária, afectando possivelmente as vias relacionadas com a inflamação e a autoimunidade. |